Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624000119594
Ethics application status
Approved
Date submitted
11/01/2024
Date registered
9/02/2024
Date last updated
9/02/2024
Date data sharing statement initially provided
9/02/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
Time Toxicity and its Relationship with Quality of Life in Patients Undergoing Phase 1 Oncology Clinical Trials
Query!
Scientific title
Time Toxicity and its Relationship with Quality of Life in Patients Undergoing Phase 1 Oncology Clinical Trials
Query!
Secondary ID [1]
311299
0
none
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Time toxicity
332541
0
Query!
Cancer
332542
0
Query!
Condition category
Condition code
Cancer
329230
329230
0
0
Query!
Any cancer
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
False
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
The Time Toxicity (TT, Days) of participation in phase 1 oncology clinical trials will be prospectively collected in patients newly enrolling in such trials for 3 months or earlier if discontinued from the trial. The TT and its impact on quality of life (QOL) of patients participating in these trials will be assessed through patient reported outcomes. TT will be measured using a ‘Participant Time Diary’ filled out by the patient and QOL will be assessed through semi-structured interviews and validated QOL questionnaires at baseline and 3 months or earlier. We estimate it may take up to 20 minutes over the course of the study to complete the 'Participant Time Diary' and up t0 40 minutes to complete the questionnaires and interviews at each time point.
Query!
Intervention code [1]
327744
0
Not applicable
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
337067
0
To prospectively measure time toxicity in participants enrolled in Phase 1 oncology clinical trials
Query!
Assessment method [1]
337067
0
Time toxicity will be measured through a 'Participant Time' diary which will be filled out by the patient to report the time they spend interacting with the healthcare system.
Query!
Timepoint [1]
337067
0
TT (days) will be measured for 3 months from commencement of the phase 1 clinical trial or earlier if the patient discontinues from the trial.
Query!
Primary outcome [2]
337226
0
To assess the impact of time toxicity on the quality of life in participants enrolled in a phase 1 oncology clinical trials
Query!
Assessment method [2]
337226
0
Two semi-structured one-on-one interviews will be conducted at two time points. The FACT-G validated questionnaire will also be used at both timepoints. We estimate approximate 40 minutes at each time point.
Query!
Timepoint [2]
337226
0
The semi-structured interviews and validated questionnaires will be conducted at baseline and 3-months from commencement of the phase 1 clinical trial or earlier if they are discontinued.
Query!
Secondary outcome [1]
430556
0
To determine the impact of phase 1 clinical trial participation on carers
Query!
Assessment method [1]
430556
0
One-on-one semi-structured interviews will be conducted at two time points and each encounter can take up to 25 minutes.
Query!
Timepoint [1]
430556
0
Baseline (commencement of phase 1 clinical trial) and at 3 months or earlier if the patient discontinues from the trial
Query!
Secondary outcome [2]
430557
0
To assess the preference of oncologists in enrolling patients onto P1 trials
Query!
Assessment method [2]
430557
0
A survey designed specifically for this study will be sent to medical oncologists in the State.
Query!
Timepoint [2]
430557
0
A standalone objective to be conducted during the course of this study
Query!
Secondary outcome [3]
430558
0
To assess the difference in expected vs actual TT in Phase 1 oncology clinical trials
Query!
Assessment method [3]
430558
0
The ‘participant time diary’ and patient’s phase 1 oncology clinical trial schedule
Query!
Timepoint [3]
430558
0
Throughout a patient’s enrolment in this study - from the patient's commencement (baseline) on the phase 1 clinical trial till 3 months or earlier if they are discontinued.
Query!
Secondary outcome [4]
431124
0
Overall survival
Query!
Assessment method [4]
431124
0
Overall survival - defined as date of death or lost to follow up.
Query!
Timepoint [4]
431124
0
From commencement of phase 1 clinical trial till up to 6 months.
Query!
Eligibility
Key inclusion criteria
1.Participants with advanced cancers recruited for Southern Oncology Clinical Research Unit Phase 1 trials from the commencement of this research study will be invited to participate.
2. Participants who are conversant in English and able to consent.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Participants who do not progress to commencing the Phase 1 clinical trial post signing this research study’s consent form.
Query!
Study design
Purpose
Query!
Duration
Longitudinal
Query!
Selection
Defined population
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
19/02/2024
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
10
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Funding & Sponsors
Funding source category [1]
315551
0
University
Query!
Name [1]
315551
0
Flinders University
Query!
Address [1]
315551
0
Flinders University, Sturt Road, Bedford Park, South Australia, 5042
Query!
Country [1]
315551
0
Australia
Query!
Primary sponsor type
University
Query!
Name
Flinders University
Query!
Address
Flinders University, Sturt Road, Bedford Park, South Australia, 5042
Query!
Country
Australia
Query!
Secondary sponsor category [1]
317639
0
None
Query!
Name [1]
317639
0
Query!
Address [1]
317639
0
Query!
Country [1]
317639
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
314450
0
Flinders University Human Research Ethics Committee
Query!
Ethics committee address [1]
314450
0
Flinders University, Sturt Road, Bedford Park, South Australia, 5042
Query!
Ethics committee country [1]
314450
0
Australia
Query!
Date submitted for ethics approval [1]
314450
0
Query!
Approval date [1]
314450
0
27/10/2023
Query!
Ethics approval number [1]
314450
0
Query!
Summary
Brief summary
Management of cancer is a rapidly evolving field, and it occurs in 4 stages: phase 1 (P1) to phase 4. P1 clinical trials are designed to test drug pharmacokinetic profiles and toxicity. However, most often patients enrol in these trials for potential therapeutic benefits. P1 trials often require participants to frequently interact with the health care team for various investigations and treatment. This time they spend interacting with the health care team has the potential to reduce quality time that participants could have utilised otherwise. This is called 'Time Toxicity' and it is defined as the time a participant spends organising and obtaining treatment including in/out-patient visits, hospitalisations, emergency care for side effects, travel and wait times, and follow-up tests. TT reported in participants undergoing cancer treatment has shown to carry a substantial burden, but its impact on the quality of life in participants undergoing P1 trials is not well explored. As such, it is often overlooked as a deciding factor in the consenting processes for the P1 trials. We aim to measure TT and assess its impact on the quality of life of participants enrolled in P1 oncology clinical trials through patient-reported outcomes. Who is it for? You may be eligible for this study if you are an adult with cancer who is going to take part in a phase 1 cancer clinical trial. Study details All participants in this study will continue with their phase 1 clinical trial, and will be asked to complete a diary for 3 months to report their time toxicity. Participants will also be asked to complete questionnaires and take part in a one-on-one interview describing their experiences and expectations at the start of the phase 1 clinical trial and after the three months (or earlier). It is hoped that this study will provide data that can help clinicians, patients, and families make the right treatment decisions.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
131626
0
Dr Shawgi Sukumaran
Query!
Address
131626
0
Flinders University, Sturt Road, Bedford Park, South Australia, 5042
Query!
Country
131626
0
Australia
Query!
Phone
131626
0
+61 8 8204 8997
Query!
Fax
131626
0
Query!
Email
131626
0
[email protected]
Query!
Contact person for public queries
Name
131627
0
Benita Rajvi
Query!
Address
131627
0
Flinders University, Sturt Road, Bedford Park, South Australia, 5042
Query!
Country
131627
0
Australia
Query!
Phone
131627
0
+61 450 910 987
Query!
Fax
131627
0
Query!
Email
131627
0
[email protected]
Query!
Contact person for scientific queries
Name
131628
0
Benita Rajvi
Query!
Address
131628
0
Flinders University, Sturt Road, Bedford Park, South Australia, 5042
Query!
Country
131628
0
Australia
Query!
Phone
131628
0
+61 450 910 987
Query!
Fax
131628
0
Query!
Email
131628
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF